Single inhalers containing corticosteroid and long-acting bronchodilator for chronic asthma in adults and children (Protocol)

Cochrane Database of Systematic Reviews

Volumn 2003, Issue 1, 2003, Pages

  Ram, Felix S F ^a   Jones, P W ^a  

^a NONE   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE PLUS FORMOTEROL; FLUTICASONE PROPIONATE PLUS SALMETEROL;

ARTICLE; ASTHMA; DRY POWDER INHALER; DYSPHONIA; HEART PALPITATION; HUMAN; INHALER; LUNG FUNCTION TEST; METERED DOSE INHALER; PRIORITY JOURNAL; QUALITY OF LIFE ASSESSMENT; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW; TACHYPHYLAXIS; TREMOR;

EID: 84991666611     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD004106     Document Type: Article

References (21)

1. Barnes PJ. Inhaled glucocorticosteroids for asthma. N Engl J Med 1995;332:868-75.
2. Burge PS, Calverley PM, Jones PW, Spencer S, Anderson JA,Maslen TK. [Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial y of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial]. BMJ 2000;320:1297-303.
3. Cazzola M, Di Perna F, D'Amato M, Califano C, Matera MG, D'Amato G. Formoterol Turbuhaler for as-needed therapy in patients with mild acute exacerbations of COPD. Respir Med 2001;95 (11):917-21.
4. Cazzola M, Grella E,Matera MG,Mazzarella G,Marsico SA. Onset of action following formoterol Turbuhaler and salbutamol pMDI in reversible chronic airway obstruction. Pulm Pharmacol Ther 2002; 15(2):97-102.
5. Cazzola M, D'Amato M, Califano C, Di Perna F, Calderaro E,MateraMG, D'AmatoG. Formoterol as dry powder oral inhalation compared with salbutamol metered-dose inhaler in acute exacerbations of chronic obstructive pulmonary disease. Clin Ther 2002a;24(4):595-604.
6. Chapman K R, Ringdahl N, Backer V, Palmqvist M, Saarelainen S, Briggs M. Salmeterol and fluticasone propionate (50/250 microg) administered via combination Diskus inhaler: as effective as when given via separate Diskus inhalers. Can Respir J 1999;6:45-51.
7. Condemi JJ.Comparison of the efficacy of formoterol and salmeterol in patients with reversible obstructive airway disease: a multicenter, randomized, open-label trial. Clin Ther 2001;23(9):1529-41.
8. Everden P, Lloyd A, Hutchinson J, Plumb J. Cost-effectiveness of eformoterol Turbohaler versus salmeterol Accuhaler in children with symptomatic asthma. Respir Med 2002;96(4):250-8.
9. Greening A J, Ind P W, Northfield M, Shaw G. Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid. Lancet 1994;344:219-24.
10. Jeppsson A-B, Källström B.-L, Waldeck B. Studies on the interaction between formoterol and salmeterol in guinea-pig trachea in vitro. Pharmacol Toxicol 1992;71:272-7.
11. Juniper E F, Kline P A, Varnzieglehem MA, Ramsdale EH, O'Byrne P M, Hargreave F E. Long-term effects of budesonide on airway responsivenes and clinical asthma severity in inhaled steroid-dependent asthmatics. Eur Respir J 1990;3:1122-7.
12. Nightingale JA, Rogers DF, Barnes PJ. Comparison of the effects of salmeterol and formoterol in patients with severe asthma. Chest 2002; 121(5):1401-6.
13. PalmqvistM, PerssonG, Lazer L, Rosenborg J, Larsson P, Lötvall J. Inhaled dry-powder formoterol and salmeterol in asthmatic patients; onset of action, duration of effect and potency. Eur Respir J 1997;10: 2484-9.
14. Palmqvist M, Ibsen T, Mellén A, Lötvall J. Comparison of the relative e.cacy of formoterol and salmeterol in asthmatic patients. Am J Respir Crit Care Med 1999;160:244-9.
15. Pauwels R A, Löfdahl C G, Postma D S, Tattersfield A E, O'Byrne P, Barnes P J,Ullman A. Effect of inhaled formoterol and budesonide on exacerbations of asthma. N Engl J Med 1997;337:1405-11.
16. Rabe KF, Jorres R, Nowak D, Behr N, Magnussen H. Comparison of the effects of salmeterol and formoterol on airway tone and responsiveness over 24 hours in bronchial asthma. Am Rev Respir Dis 1993;147(6):1436-41.
17. Ulrik CS, Kok-Jensen A. Different bronchodilating effect of salmeterol and formoterol in an adult asthmatic. Eur Respir J 1994;7(5): 1003-5.
18. van der Molen T, Postma D S, Turner M O, Meyboom-de Jong B, Malo J L, Chapman K, Grossman R, de Gra. C S, Riermersma R A, Sears M R. Effect of the long-acting beta agonist formoterol on asthma control in asthmatic patients using inhaled corticosteroids. Thorax 1997;52:535-9.
19. vanNoord J, Smeets J J, Raaijmakers J AM, Bommer AM,Maesen F P V. Salmeterol versus formoterol in patients with moderately severe asthma: onset and duration of action. Eur Respir J 1996;9:1684-8.
20. Zetterström O, Buhl R,Mellem H, PerpinaM,Hedman J, O'Neill S, Peterson S control in adults. The new single inhaler product containing both budesonide/formoterol improves asthma. Eur Respir J 2000:A186.
21. Zetterström O, Buhl R,Mellem H, PerpinaM,Hedman J, O'Neill S, Ekström T. Effcacy and safety of a new single inhaler product, containing both budesonide and formoterol, in adult asthma. Eur Respir J 2000a:A186.